Last reviewed · How we verify
Darbepoetin
At a glance
| Generic name | Darbepoetin |
|---|---|
| Also known as | Darbe, EPO |
| Sponsor | NICHD Neonatal Research Network |
| Target | Erythropoietin receptor |
| Modality | Small molecule |
| Therapeutic area | Hematology |
| Phase | FDA-approved |
Approved indications
- Anemia due to and following chemotherapy
- Anemia of renal disease
Common side effects
- Hypertension
- Injection site pain
- Rash
- Convulsions
Serious adverse events
- Hypertension
- Convulsions
- Cerebrovascular disorders
- Thromboembolic adverse reactions
Key clinical trials
- Luspatercept + Darbepoetin in MDS (PHASE2)
- Vafseo Outcomes In-Center Experience (PHASE3)
- Choices About Genetic Testing And Learning Your Risk With Smart Technology (NA)
- Darbe Plus IV Iron to Decrease Transfusions While Maintaining Iron Sufficiency in Preterm Infants (PHASE2)
- Efficacy and Safety Study to Evaluate MT-6548 in Non-dialysis Subjects With Anemia Associated With Chronic Kidney Disease in Japan (PHASE3)
- Efficacy and Safety Study to Evaluate MT-6548 in Hemodialysis Subjects Currently Receiving ESAs With Anemia Associated With Chronic Kidney Disease in Japan (PHASE3)
- A Study to Evaluate Efficacy and Safety of QLG1218(Daprodustat) in Chinese Hemodialysis (HD)-Dependent Subjects With Anemia Associated With Chronic Kidney Disease (CKD) (PHASE3)
- Darbepoetin in Patients Candidates for Liver Transplant. (EPO-LT Trial) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Darbepoetin CI brief — competitive landscape report
- Darbepoetin updates RSS · CI watch RSS
- NICHD Neonatal Research Network portfolio CI